BIIB Q1 2019 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q1 2019 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$3.5B+11.5% YoY

Gross Profit

$2.9B82.7% margin

Operating Income

$1.5B43.1% margin

Net Income

$1.4B40.4% margin

EPS (Diluted)

$7.15

QoQ Revenue Growth

-1.0%

Cash Flow

Operating Cash Flow

$1.5B

Free Cash Flow

$1.3B

Stock-Based Comp.

$46M

Balance Sheet

Total Assets

$26.4B

Total Liabilities

$12.6B

Stockholders' Equity

$13.8B

Cash & Equivalents

$2.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.5B	$3.1B	+11.5%
Gross Profit	$2.9B	$2.7B	+7.5%
Operating Income	$1.5B	$1.5B	-2.1%
Net Income	$1.4B	$1.2B	+20.1%

Revenue Segments

MS Product Revenues

$2.0B57%

SPINRAZA

$519M15%

Interferon

$501M14%

TYSABRI product

$460M13%

Geographic Segments

UNITED STATES

$1.5B56%

Non-US

$1.2B44%